ES1310363U - COSMETIC COMPOSITION OF LIPOSOMES CONTAINING COENZYME Q10 - Google Patents
COSMETIC COMPOSITION OF LIPOSOMES CONTAINING COENZYME Q10 Download PDFInfo
- Publication number
- ES1310363U ES1310363U ES202332013U ES202332013U ES1310363U ES 1310363 U ES1310363 U ES 1310363U ES 202332013 U ES202332013 U ES 202332013U ES 202332013 U ES202332013 U ES 202332013U ES 1310363 U ES1310363 U ES 1310363U
- Authority
- ES
- Spain
- Prior art keywords
- weight
- composition
- coenzyme
- cosmetic composition
- polyglyceryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 28
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 title claims abstract description 14
- 239000002502 liposome Substances 0.000 title claims abstract description 11
- 239000002537 cosmetic Substances 0.000 title claims abstract description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 14
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims abstract description 14
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000017471 coenzyme Q10 Nutrition 0.000 claims abstract description 12
- 229940110767 coenzyme Q10 Drugs 0.000 claims abstract description 9
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims abstract description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 7
- 229930195725 Mannitol Natural products 0.000 claims abstract description 7
- 229960000541 cetyl alcohol Drugs 0.000 claims abstract description 7
- 239000000594 mannitol Substances 0.000 claims abstract description 7
- 235000010355 mannitol Nutrition 0.000 claims abstract description 7
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims abstract description 7
- 229940097941 polyglyceryl-10 laurate Drugs 0.000 claims abstract description 7
- 235000010241 potassium sorbate Nutrition 0.000 claims abstract description 7
- 239000004302 potassium sorbate Substances 0.000 claims abstract description 7
- 229940069338 potassium sorbate Drugs 0.000 claims abstract description 7
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims abstract description 7
- 235000010234 sodium benzoate Nutrition 0.000 claims abstract description 7
- 239000004299 sodium benzoate Substances 0.000 claims abstract description 7
- 239000011780 sodium chloride Substances 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000006185 dispersion Substances 0.000 claims abstract description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 3
- 229940035936 ubiquinone Drugs 0.000 description 3
- 239000005515 coenzyme Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000027721 electron transport chain Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
DESCRIPCIÓNDESCRIPTION
COMPOSICIÓN COSMÉTICA DE LIPOSOMAS QUE CONTIENEN COENZIMA Q10 COSMETIC COMPOSITION OF LIPOSOMES CONTAINING COENZYME Q10
SECTOR DE LA TÉCNICATECHNICAL SECTOR
La presente invención pertenece al campo de la cosmética y se refiere a una composición cosmética formada por liposomas que contiene la coenzima ubiquinona (coenzima Q10). The present invention belongs to the field of cosmetics and relates to a cosmetic composition formed by liposomes containing the coenzyme ubiquinone (coenzyme Q10).
ANTECEDENTES DE LA INVENCIÓNBACKGROUND OF THE INVENTION
En la sociedad actual existe una gran preocupación por cuidar y proteger la piel como primera barrera para mantener la salud. El deterioro de las condiciones medioambientales como el aumento de contaminación y una radiación solar cada vez más agresiva incrementan los procesos oxidativos sobre la piel que conducen a su degeneración acelerada. Existe la necesidad de una protección adecuada de la piel y los consumidores requieren que los productos cosméticos tengan una estabilidad y efectividad cada vez mayor. Estos factores suponen un reto a la industria cosmética para el desarrollo de sus productos. In today's society there is a great concern about caring for and protecting the skin as the first barrier to maintaining health. The deterioration of environmental conditions such as increased pollution and increasingly aggressive solar radiation increase oxidative processes on the skin that lead to accelerated degeneration. There is a need for adequate skin protection and consumers require cosmetic products to be increasingly stable and effective. These factors pose a challenge to the cosmetics industry in the development of its products.
DESCRIPCIÓN DE LA INVENCIÓNDESCRIPTION OF THE INVENTION
La presente invención se refiere a una composición cosmética que comprende una solución acuosa y estable de liposomas que contienen la coenzima ubiquinona, también conocida como coenzima Q10, en su composición. Esta sustancia liposoluble está presente en la mayoría de las células eucariotas, principalmente en la mitocondria. Es un componente de la cadena de transporte de electrones y participa en la respiración celular aeróbica, generando energía en forma de ATP. Al formar parte de la membrana del liposoma, la ubiquinona se liberará en el estrato de la piel a donde el liposoma sea dirigido y por tanto ejercerá sus efectos beneficiosos en esa zona de la piel donde se libere. The present invention relates to a cosmetic composition comprising a stable aqueous solution of liposomes containing the coenzyme ubiquinone, also known as coenzyme Q10, in its composition. This liposoluble substance is present in most eukaryotic cells, mainly in the mitochondria. It is a component of the electron transport chain and participates in aerobic cellular respiration, generating energy in the form of ATP. By forming part of the liposome membrane, the ubiquinone will be released in the skin layer where the liposome is directed and will therefore exert its beneficial effects in that area of the skin where it is released.
Los liposomas son vesículas esféricas con una membrana compuesta de una doble capa de fosfolípidos, que constan de partes hidrosolubles y liposolubles. Los liposomas son osmóticamente activos y estables y presentan numerosas ventajas, como su buen poder de solubilización o su capacidad de aumentar la estabilidad de una molécula contenida en ellos debido a la carga eléctrica de su superficie. Además, son biodegradables, biocompatibles y no inmunogénicos y exhiben una buena estabilidad coloidal, química y biológica. Liposomes are spherical vesicles with a membrane composed of a double layer of phospholipids, consisting of water-soluble and fat-soluble parts. Liposomes are osmotically active and stable and have numerous advantages, such as their good solubilizing power or their ability to increase the stability of a molecule contained in them due to the electrical charge of their surface. In addition, they are biodegradable, biocompatible and non-immunogenic and exhibit good colloidal, chemical and biological stability.
La presente invención se refiere a una composición cosmética, en forma de una dispersión acuosa y estable de liposomas, caracterizada por tener los siguientes componentes: a. entre 4,00 y 7,00 % en peso de fosfatidilcolina, The present invention relates to a cosmetic composition, in the form of a stable aqueous dispersion of liposomes, characterized by having the following components: a. between 4.00 and 7.00% by weight of phosphatidylcholine,
b. entre 0,60 y 0,90 % en peso de cetil-alcohol, b. between 0.60 and 0.90% by weight of cetyl alcohol,
c. entre 4,00 y 7,00 % en peso de manitol, c. between 4.00 and 7.00% by weight of mannitol,
d. entre 2,00 y 5,00 % en peso de glicerol, d. between 2.00 and 5.00% by weight of glycerol,
e. entre 0,50 y 1,00 % en peso de sorbato potásico, e. between 0.50 and 1.00% by weight of potassium sorbate,
f. entre 0,50 y 1,00 % en peso de benzoato sódico, f. between 0.50 and 1.00% by weight of sodium benzoate,
g. entre 0,05 y 0,20 % en peso de cloruro sódico, g. between 0.05 and 0.20% by weight of sodium chloride,
h. entre 0,50 y 1,50 % en peso de poligliceril 10 laurato, h. between 0.50 and 1.50% by weight of polyglyceryl-10 laurate,
i. entre 0,025 y 1,50 % en peso de coenzima Q10, i. between 0.025 and 1.50% by weight of coenzyme Q10,
j. opcionalmente entre 15 y 25 % en peso de etanol, j. optionally between 15 and 25% by weight of ethanol,
k. opcionalmente entre 0,50 y 3,50 % en peso de ácido cítrico, k. optionally between 0.50 and 3.50% by weight of citric acid,
l. agua preferiblemente hasta completar el 100,00 % en peso, l. water preferably up to 100.00% by weight,
donde dichos % en peso son con respecto al peso total de la composición. where said % by weight are with respect to the total weight of the composition.
En una realización preferida de la invención, la composición se caracteriza por que tiene los siguientes componentes: In a preferred embodiment of the invention, the composition is characterized in that it has the following components:
a. entre 5,00 y 6,00 % en peso de fosfatidilcolina, a. between 5.00 and 6.00% by weight of phosphatidylcholine,
b. entre 0,70 y 0,80 % en peso de cetil-alcohol, b. between 0.70 and 0.80% by weight of cetyl alcohol,
c. entre 5,00 y 6,00 % en peso de manitol, c. between 5.00 and 6.00% by weight of mannitol,
d. 3,29 % en peso de glicerol, d. 3.29% by weight of glycerol,
e. entre 0,55 y 0,80 % en peso de sorbato potásico, e. between 0.55 and 0.80% by weight of potassium sorbate,
f. entre 0,55 y 0,80 % en peso de benzoato sódico, f. between 0.55 and 0.80% by weight of sodium benzoate,
g. entre 0,08 y 0,15 % en peso de cloruro sódico, g. between 0.08 and 0.15% by weight of sodium chloride,
h. entre 0,90 y 1,30 % en peso de poligliceril 10 laurato, h. between 0.90 and 1.30% by weight of polyglyceryl-10 laurate,
i. entre 0,05 y 1,0 % en peso coenzima Q10, i. between 0.05 and 1.0% by weight coenzyme Q10,
j. agua hasta 100 % en peso, j. water up to 100% by weight,
donde dichos % en peso son con respecto al peso total de la composición. where said % by weight are with respect to the total weight of the composition.
En una realización más preferida de la presente invención, la composición comprende: a. 5,50 % en peso de fosfatidilcolina, In a more preferred embodiment of the present invention, the composition comprises: a. 5.50% by weight of phosphatidylcholine,
b. 0,74 % en peso de cetil-alcohol, b. 0.74% by weight of cetyl alcohol,
c. 5,74 % en peso de manitol, c. 5.74% by weight of mannitol,
d. 3,29 % en peso de glicerol, d. 3.29% by weight of glycerol,
e. 0,60 % en peso de sorbato potásico, and. 0.60% by weight of potassium sorbate,
f. 0,60 % en peso de benzoato sódico, f. 0.60% by weight of sodium benzoate,
g. 0,10 % en peso de cloruro sódico, g. 0.10% by weight of sodium chloride,
h. 1,23 % en peso de poligliceril 10 laurato, h. 1.23% by weight of polyglyceryl-10 laurate,
i. 0,07 % en peso de coenzima Q10, i. 0.07% by weight of coenzyme Q10,
j. 79,68 % en peso de agua, j. 79.68% by weight of water,
donde dichos % en peso son con respecto al peso total de la composición. where said % by weight are with respect to the total weight of the composition.
EJEMPLOSEXAMPLES
Esta invención se entenderá mejor por referencia a los ejemplos a continuación, pero aquellos expertos en la técnica apreciaran fácilmente que los ejemplos específicos detallados solamente son ilustrativos de la invención. This invention will be better understood by reference to the following examples, but those skilled in the art will readily appreciate that the specific examples detailed are only illustrative of the invention.
Ejemplo 1: Composición.Example 1: Composition.
*Todos los porcentajes son en peso con respecto al peso total de la composición. *All percentages are by weight relative to the total weight of the composition.
La composición es homogénea y estable y constituye un excelente producto para la salud de la piel. The composition is homogeneous and stable and constitutes an excellent product for skin health.
Claims (4)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES202330041 | 2023-01-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES1310363U true ES1310363U (en) | 2024-09-09 |
| ES1310363Y ES1310363Y (en) | 2024-12-02 |
Family
ID=92633334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES202332013U Active ES1310363Y (en) | 2023-01-12 | 2023-11-13 | COSMETIC COMPOSITION OF LIPOSOMES CONTAINING COENZYME Q10 |
Country Status (1)
| Country | Link |
|---|---|
| ES (1) | ES1310363Y (en) |
-
2023
- 2023-11-13 ES ES202332013U patent/ES1310363Y/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES1310363Y (en) | 2024-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2768323T3 (en) | Cosmetic compositions containing at least one hydrotrope and at least one active compound | |
| ES2620442T3 (en) | Use of tetrakis (N-alkylpyridinium) -porphyrin derivatives for the destruction of microbes or the prevention of their growth | |
| ES2390015T3 (en) | Cosmetic composition comprising a hydroxylated diphenyl methane derivative | |
| ES2131428T3 (en) | COSMETIC USE OF A POLY (2-ACRYLAMIDE 2-METHYLPROPAN SULPHONIC ACID) RETICULATED AND NEUTRALIZED IN AT LEAST 90% AND TOPICAL COMPOSITIONS THAT CONTAIN THEM. | |
| ES2183427T3 (en) | PREPARATION FOR HAIR DYING. | |
| US20040028631A1 (en) | Cosmetic formulations | |
| ES2081174T3 (en) | DETERGENT COMPOSITIONS. | |
| AR090122A1 (en) | TOPICAL COMPOSITIONS THAT INCLUDE FIPRONYL AND PERMETRINE AND THEIR METHODS OF USE | |
| CN113648236A (en) | Antioxidant composition, antioxidant cosmetic composition and preparation method thereof | |
| ES2408342T3 (en) | Use of osmolytes obtained from extremophilic bacteria for the preparation of drugs for the external treatment of neurodermatitis | |
| PT1411889E (en) | Cream for treatment of skin injured by the sun | |
| ES1310363U (en) | COSMETIC COMPOSITION OF LIPOSOMES CONTAINING COENZYME Q10 | |
| ES2161364T3 (en) | STABILIZED PSEUDOEMULSIONS AND THEIR PREPARATION PROCEDURE. | |
| ES2123790T3 (en) | PROCEDURE FOR THE PREPARATION OF IODATED BIOPOLYMERS THAT HAVE DISINFECTING AND HEALING ACTIVITY, AND THE IODATED BIOPOLYMERS OBTAINED BY SUCH PROCEDURE. | |
| ES2280495T3 (en) | COSMETIC COMPOSITIONS CONTAINING ARCHAOBACTERY EXTRACTS. | |
| US4098881A (en) | Compositions to control the chronic effects of exposure to sunlight comprising conjugated dienes | |
| Rub | Effect of additives (TX-114) on micellization and microstructural phenomena of amphiphilic ibuprofen drug (sodium salt): Multi-technique approach | |
| CA2287257C (en) | 1,2,4-benzotriazine oxides formulations | |
| ES1306374U (en) | COSMETIC COMPOSITION OF LIPOSOMES CONTAINING THE FLAVONOID HESPERIDIN (Machine-translation by Google Translate, not legally binding) | |
| CN104188819B (en) | A kind of hyaluronic acid scattered hesperetin nanometer cosmetic water and preparation method thereof | |
| KR102147642B1 (en) | Cosmetic composition for acne improvement | |
| US4132774A (en) | Method of and composition for screening erythema inducing ultraviolet bands | |
| ES1265629U (en) | Cosmetic composition of liposomes containing a quaternized derivative of 18-methyl eicosanoic acid (Machine-translation by Google Translate, not legally binding) | |
| RU2379026C2 (en) | Composition for fluorescent diagnostics and photodynamic therapy | |
| CA2232989C (en) | 1,2,4-benzotriazine oxides formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CA1K | Utility model application published |
Ref document number: 1310363 Country of ref document: ES Kind code of ref document: U Effective date: 20240909 |
|
| FG1K | Utility model granted |
Ref document number: 1310363 Country of ref document: ES Kind code of ref document: Y Effective date: 20241126 |